Aura Biosciences Reports Third Quarter 2023 Financial Result

Received FDA Agreement Under Special Protocol Assessment (SPA) for the CoMpass Phase 3 Clinical TrialPositive Clinical Efficacy Updates of Bel-sar for Early-Stage Choroidal Melanoma from the Ongoing Phase 2 Clinical Trial with Suprachoroidal Administration Presented at AAO 2023Preliminary Data from Phase 1 Trial in...

Related Keywords

United States , Boston , Massachusetts , Los Pinos , J Jill Hopkins , Mark Plavsic , Technology Officer , Suprachoroidal Administration , Twitter , Novartis Company , Oncology Division , Company Phase , Nasdaq , Aura Biosciences Inc , Exchange Commission , Linkedin , Exploratory Development At Novartis , Company Global Phase , Under Special Protocol Assessment , Compass Phase , Clinical Efficacy Updates , Early Stage Choroidal Melanoma , Ongoing Phase , Suprachoroidal Administration Presented , Bladder Cancer , First Patient Utilizing , Single Dose , Light Activation Demonstrated , Clinical Complete , Gross Proceeds , Underwritten Public , Aura Biosciences , Elisabet De Los Pinos , Chief Executive Officer , Fast Track Designation , Chief Medical Officer , Senior Vice President , Global Head , Exploratory Development , Gyroscope Therapeutics , Chief Technology , Chief Technology Officer , Fate Therapeutics , Global Phase , Private Securities Litigation Reform Act , Annual Report , Quarterly Report , Comprehensive Loss ,